|
🐜
|
Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention
40 auth.
A. Lennon,
A. Buchanan,
Isaac Kinde,
A. Warren,
A. Honushefsky,
A. Cohain,
D. Ledbetter,
Fred Sanfilippo,
Kathleen Sheridan,
D. Rosica,
C. Adonizio,
Heejung Hwang,
Kamel Lahouel,
J. Cohen,
C. Douville,
...
Aalpen A. Patel,
Leonardo N. Hagmann,
D. Rolston,
N. Malani,
Shibin Zhou,
C. Bettegowda,
D. Diehl,
B. Urban,
C. Still,
L. Kann,
Julie I Woods,
Zachary M. Salvati,
Joseph Vadakara,
R. Leeming,
Prianka Bhattacharya,
Carroll Walter,
A. Parker,
C. Lengauer,
A. Klein,
C. Tomasetti,
E. Fishman,
R. Hruban,
K. Kinzler,
B. Vogelstein,
N. Papadopoulos
|
8 |
2020 |
8
🐜
|
|
🐜
|
Pegylated Interferon Alfa-2a for Polycythemia Vera or Essential Thrombocythemia Resistant or Intolerant to Hydroxyurea.
34 auth.
A. Yacoub,
J. Mascarenhas,
H. Kosiorek,
J. Prchal,
Dmitriy Berenzon,
M. Baer,
E. Ritchie,
R. Silver,
C. Kessler,
E. Winton,
M. Finazzi,
A. Rambaldi,
A. Vannucchi,
D. Leibowitz,
D. Rondelli,
...
M. Arcasoy,
R. Catchatourian,
Joseph Vadakara,
V. Rosti,
E. Hexner,
M. Kremyanskaya,
L. Sandy,
J. Tripodi,
V. Najfeld,
N. Farnoud,
E. Papaemmanuil,
M. Salama,
Rona Singer-Weinberg,
R. Rampal,
J. Goldberg,
T. Barbui,
R. Mesa,
A. Dueck,
R. Hoffman
|
7 |
2019 |
7
🐜
|
|
🦁
|
Gastrointestinal stromal tumors: management of metastatic disease and emerging therapies.
Joseph Vadakara,
M. von Mehren
|
4 |
2013 |
4
🦁
|
|
🦁
|
Personalized medicine and treatment approaches in non-small-cell lung carcinoma
Joseph Vadakara,
H. Borghaei
|
4 |
2012 |
4
🦁
|
|
🐜
|
A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis
32 auth.
J. Mascarenhas,
H. Kosiorek,
J. Prchal,
A. Yacoub,
Dmitriy Berenzon,
M. Baer,
E. Ritchie,
R. Silver,
C. Kessler,
E. Winton,
M. Finazzi,
A. Rambaldi,
A. Vannucchi,
D. Leibowitz,
D. Rondelli,
...
M. Arcasoy,
R. Catchatourian,
Joseph Vadakara,
V. Rosti,
E. Hexner,
M. Kremyanskaya,
L. Sandy,
J. Tripodi,
V. Najfeld,
N. Farnoud,
M. Salama,
R. Weinberg,
R. Rampal,
J. Goldberg,
R. Mesa,
A. Dueck,
R. Hoffman
|
4 |
2019 |
4
🐜
|
|
🐢
|
Etiologies and Short-Term Mortality in Patients with Ultraelevated Serum Ferritin
T. Beer,
Joseph Vadakara
|
4 |
2015 |
4
🐢
|
|
🦁
|
Targeting CD30 in Anaplastic Large Cell Lymphoma
Joseph Vadakara,
B. Pro
|
3 |
2012 |
3
🦁
|
|
🐜
|
Single-Arm Salvage Therapy with Pegylated Interferon Alfa-2a for Patients with High-Risk Polycythemia Vera or High-Risk Essential Thrombocythemia Who Are Either Hydroxyurea-Resistant or Intolerant: Final Results of the Myeloproliferative Disorders-Research Consortium (MPD-RC) Protocol 111 Global Pha
32 auth.
A. Yacoub,
J. Mascarenhas,
H. Kosiorek,
J. Prchal,
Dmitriy Berenzon,
M. Baer,
E. Ritchie,
R. Silver,
C. Kessler,
E. Winton,
M. Finazzi,
A. Rambaldi,
A. Vannucchi,
D. Leibowitz,
D. Rondelli,
...
M. Arcasoy,
R. Catchatourian,
Joseph Vadakara,
V. Rosti,
E. Hexner,
M. Kremyanskaya,
Alicia Orellana,
L. Sandy,
J. Tripodi,
V. Najfeld,
M. Salama,
R. Weinberg,
R. Rampal,
R. Mesa,
J. Goldberg,
A. Dueck,
R. Hoffman
|
3 |
2017 |
3
🐜
|
|
🦁
|
Management of Metastatic Disease and Emerging Therapies
Joseph Vadakara,
M. Mehren
|
2 |
2013 |
2
🦁
|
